An adult told a few years ago that the RSV vaccine starts at 60 while remembering real guidance. That age threshold has changed twice since then, and who qualifies now depends both on age and on whether one of the risk conditions identified by CDC appears in your health history.
Blue Point’s guide to the vaccines adults may need this fall covers the broader adult immunization schedule. This page focuses specifically on RSV vaccination because eligibility depends on a combination of age, medical history, and current CDC recommendations.
The two tiers that decide it, and the number that is no longer one
CDC’s page on RSV vaccine guidance for adults, revised Feb. 24, 2026, states that CDC recommends a single dose of respiratory syncytial virus vaccine for all adults ages 75 and older and for adults ages 50 through 74 who are at increased risk of severe RSV illness.
CDC’s vaccine notes, dated July 2, 2025, separate those groups structurally. Adults aged 75 and older fall under routine vaccination, while adults ages 50 through 74 fall under special situations, with one dose recommended and additional doses not currently recommended. Age alone qualifies someone at 75. Below that age, a risk factor is required.
Nothing in either document creates a separate rule specifically for adults ages 50 through 59. A 52-year-old and a 72-year-old are both evaluated under the same risk-based tier.
Age 60 still appears in some vaccine materials, but it is no longer the current CDC recommendation threshold. It may still appear in older guidance or in product licensure information, which is one reason different sources may seem to give different answers.
In primary care, RSV eligibility is therefore a two-step check: age first, followed by a review of risk factors when the patient is younger than 75.
The risk conditions, and the two exclusions written inside them
CDC lists several conditions that increase the risk of severe RSV illness.
The first group includes chronic cardiovascular disease, such as heart failure, coronary artery disease and congenital heart disease, and chronic lung or respiratory disease, including chronic obstructive pulmonary disease (COPD), emphysema, asthma, interstitial lung disease and cystic fibrosis.
End-stage renal disease also qualifies, particularly when a person depends on hemodialysis or another form of renal replacement therapy. That category is narrower than kidney disease in general.
Diabetes mellitus qualifies under more specific circumstances. CDC lists diabetes complicated by chronic kidney disease, neuropathy, retinopathy or other end-organ damage, or diabetes requiring treatment with insulin or a sodium-glucose cotransporter-2 (SGLT2) inhibitor. That means the diagnosis alone does not necessarily determine eligibility.
Additional conditions include chronic liver disease, such as cirrhosis, and chronic hematologic conditions, including sickle cell disease and thalassemia.
Other qualifying categories include moderate or severe immune compromise, severe obesity with a body mass index of 40 kg/m² or higher, and residence in a nursing home.
For someone managing more than one chronic condition, more than one category may apply, but a single qualifying risk factor may be enough.
Isolated high blood pressure, and a stroke that left no impairment
CDC includes two important exclusions inside its risk-factor definitions.
The cardiovascular category specifically excludes isolated hypertension. High blood pressure by itself does not qualify someone for RSV vaccination under this risk category.
The neurologic category is also specific. It covers conditions that impair airway clearance or cause respiratory muscle weakness, with examples such as poststroke dysphagia, amyotrophic lateral sclerosis and muscular dystrophy.
A history of stroke without impaired airway clearance does not qualify under that neurologic category. The distinction depends on the functional effects of the condition rather than the diagnosis alone.
COPD and asthma, with no severity threshold and one age limit
The chronic lung category is broader in one important way. CDC specifically includes COPD, emphysema, asthma, interstitial lung disease and cystic fibrosis without attaching a severity threshold to those diagnoses.
That differs from diabetes, where CDC includes additional clinical requirements, and from neurologic disease, where impaired airway clearance or respiratory muscle weakness is required.
The important boundary is age. Chronic lung disease qualifies a person only once the risk-based recommendation begins at age 50. Adults younger than 50 fall outside the current CDC recommendation even if they have COPD or asthma.
Local factors such as air quality and monsoon dust may aggravate respiratory symptoms, and pulmonary function testing can help document lung function, but neither changes the age threshold for RSV vaccination.
Attestation, not documentation
One of the most practical parts of the CDC guidance is that patient attestation is sufficient evidence of a risk factor. CDC states that vaccinators should not deny RSV vaccination solely because the patient does not have medical documentation with them.
That means a person does not necessarily need to bring records, a physician letter or a diagnosis code to prove the presence of a qualifying condition.
Knowing which risk factor applies is still useful, especially when eligibility depends on details such as whether diabetes is treated with insulin or an SGLT2 inhibitor. A medication review can help clarify those details.
CDC also leaves room for provider judgment. Its guidance includes other chronic conditions or risk factors that a healthcare provider determines increase the risk of severe disease from viral respiratory infections. Examples include frailty, concern about undiagnosed conditions, and living in a remote or rural area where access to higher-level medical care may be difficult.
That flexibility means the listed conditions guide the decision without necessarily covering every possible situation.
One dose, and the window that makes it worth timing
CDC currently recommends the RSV vaccine as a single dose, not as an annual vaccine.
People who have already received one RSV vaccine dose are considered to have completed the current recommendation and should not receive another dose at this time.
CDC continues to monitor how long protection lasts and whether additional doses could be beneficial in the future. For now, however, the recommendation remains a single dose.
Available evidence supports that approach. CDC has reported that one RSV vaccine dose can provide protection for at least two RSV seasons.
Late summer to early fall, and why that differs from the pneumococcal answer
Eligible adults can receive the RSV vaccine at any time of year, but CDC states that vaccination generally provides the most benefit when given in late summer or early fall, shortly before RSV season.
For most of the continental United States, CDC identifies August through October as the preferred timing window.
That makes RSV different from pneumococcal vaccination, which is not tied to a seasonal window. The RSV vaccine is still a one-time dose, but timing it shortly before RSV season may provide the greatest benefit.
An annual wellness visit in early fall can be a convenient opportunity to review RSV eligibility along with the rest of the vaccination history.
The reason every other page gives a different answer
RSV vaccine recommendations have changed quickly, which is why older but otherwise reputable sources may show different ages.
The original adult recommendation, issued in 2023, allowed adults age 60 and older to receive a single dose through shared clinical decision-making.
In 2024, ACIP changed that approach. Routine RSV vaccination was recommended for adults age 75 and older, while adults ages 60 through 74 were recommended to receive the vaccine only if they were at increased risk for severe RSV disease.
In 2025, the risk-based recommendation was expanded downward to include adults ages 50 through 59. That created the current structure: routine vaccination beginning at 75 and risk-based vaccination from ages 50 through 74.
Because different websites and reference materials update at different times, older guidance may still refer to age 60 or shared clinical decision-making.
Licensed from 18, recommended from 50
Another source of confusion is the difference between FDA licensure and CDC recommendations.
Some RSV vaccines are licensed for adults ages 18 through 49 who are at increased risk of severe RSV lower respiratory tract disease. That does not mean CDC currently recommends routine or risk-based vaccination for every person in that age group.
Under current CDC guidance, the risk-based recommendation starts at age 50.
A vaccine manufacturer’s page may therefore list a broader licensed age range than the CDC immunization schedule. Licensure determines who a product may legally be used for, while CDC recommendations determine how the vaccine is incorporated into the routine adult vaccination schedule.
Frequently Asked Questions
Can I get the RSV vaccine at the same visit as a flu or COVID-19 vaccine?
Yes. CDC states that RSV vaccines can be coadministered with other adult vaccines during the same visit.
However, available data on immune response when RSV vaccines are given alongside other respiratory virus vaccines are still limited. CDC notes that antibody levels may be somewhat lower with coadministration, although the clinical significance of that finding is not yet known.
Your physician or vaccine provider can help determine whether receiving multiple vaccines at the same visit makes sense for you.
Can the RSV vaccine be given during pregnancy?
RSV vaccination during pregnancy follows a different recommendation from the general adult schedule.
Only Abrysvo is licensed for use during pregnancy, specifically at 32 through 36 weeks of gestational age. Other RSV vaccines are not approved for that use.
The decision should be made with the physician managing the pregnancy, who can review timing, health history and current recommendations.
Which RSV vaccine should adults receive?
CDC currently names three FDA-licensed RSV vaccines for eligible adults: Arexvy, mResvia and Abrysvo.
CDC does not currently recommend one of these vaccines over the others for eligible adults. In most cases, an appropriate vaccine that is licensed for the patient’s age group and available at the practice or pharmacy can be used.
RSV Vaccine Eligibility Depends on Both Age and Health History
The current RSV vaccine recommendations for adults are more specific than the older age-60 rule many people remember. Adults aged 75 and older qualify based on age alone, while adults ages 50 through 74 may qualify when they have a condition or other factor that increases their risk of severe RSV illness.
Conditions such as COPD, asthma, certain forms of diabetes, cardiovascular disease, immune compromise, severe obesity, and end-stage renal disease can affect eligibility. At the same time, some common conditions, including isolated high blood pressure, do not automatically qualify someone.
The vaccine is currently recommended as a single dose, and for most eligible adults, late summer or early fall is the preferred time to receive it before RSV season begins.
If you are unsure whether you qualify for the RSV vaccine, contact Blue Point Medical Group to schedule an appointment. Our primary care team can review your age, health conditions, vaccination history, and current medications to help determine whether RSV vaccination may be appropriate for you.
This article is for informational purposes only and does not constitute medical advice. Always consult your physician or a qualified healthcare provider for questions about your health or before making changes to your treatment plan.
